Patented Technology

TABMELT®

Novel Patented Technology to Make Blockbuster Medications Better

TABMELT is a novel patented and patent-pending sublingual drug delivery system that allows patients to take a medication by simply dissolving a tablet under their tongue. This delivery route may lead to more instantaneous and accurate absorption than that of oral drug delivery.

TABMELT BioSciences Patents

Cardiovascular

Jurisdiction Compound Patent Status
United States VVRA – TM 001 Published; March 2022

Central Nervous System

Jurisdiction Compound Patent Status
United States VVRA – TM 002 Published; December 2021
United States VVRA – TM 003 Published; March 2021
United States VVRA – TM 005 Published; December 2021
United States PTNR – TM 006 Published; April 2022
United States PTNR – TM 007 Published; April 2022

Childhood-Onset Fluency Disorder (Stuttering)

Jurisdiction Compound Patent Status
United States VVRA – TM 008 Published; January 2022
United States VVRA – TM 009 Published; April 2023

Oncology

Jurisdiction Compound Patent Status
United States VVRA – TM 004 Published; June 2022

Licensed TABMELT Patents

Jurisdiction Title Patent Status
Australia All Natural, Non-Toxic Sublingual Drug Delivery Systems Granted; August 2015
United Kingdom All Natural, Non-Toxic Sublingual Drug Delivery Systems Granted; May 2018
Canada All Natural, Non-Toxic Sublingual Drug Delivery Systems Granted; July 2018
Russia All Natural, Non-Toxic Sublingual Drug Delivery Systems Granted; October 2020
Israel All Natural, Non-Toxic Sublingual Drug Delivery Systems Granted; February 2022
United States All Natural, Non-Toxic Sublingual Drug Delivery Systems Published; June 2019
World Intellectual Property Organization All Natural, Non-Toxic Sublingual Drug Delivery Systems Published, October 2015
Japan All Natural, Non-Toxic Sublingual Drug Delivery Systems Filed
Mexico All Natural, Non-Toxic Sublingual Drug Delivery Systems Filed
China All Natural, Non-Toxic Sublingual Drug Delivery Systems Filed

MEDICAL & SCIENTIFIC LEADS

Dr. McColgan

Stephen J. McColgan, M.D. M.B.A.

Chief Medical Officer
  • 68 invited presentations, 12 publications
  • 35 years of surgical experience, 30+ years of experience in medical & surgical device development
  • Developed enhanced laparoscopic devices for a medical technology company, driving acquisition by a major publicly-traded company
  • Clinical instructor, professional consultant
  • Currently developing ZICOH and endomechanical devices for cardiovascular medicine and surgery
Bobby W. Sandage

Bobby W. Sandage, Jr., Ph.D.

Drug Development Advisor
  • 3 patents issued, 50+ scientific articles 
  • 35+ years of experience in drug development, regulatory affairs, & life sciences venture capital 
  • Guided development for 35 products/programs
  • Achieved regulatory approval for 12 drugs and 1 device
  • Adjunct professor of pharmaceutical sciences
  • Drug Development Institute advisor for the Ohio State University Comprehensive Cancer Center
Dr. Maguire

Gerald A. Maguire, M.D., D.L.F.A.P.A.

Chief Neurosciences Advisor
  • Person who stutters and subject matter expert
  • 76 publications on stuttering—the most published doctor in the space
  • PI for the first investigational drug for stuttering in adults
  • Hundreds of invited presentations on stuttering
  • Professor of psychiatry, clinical trialist (PI of 40+ clinical trials for 25+ years)
  • Chair of R&D for World Stuttering Network
headshot

Dennis Moore

Regulatory and Compliance Advisor
  • Former United States Food and Drug Administration (FDA) Investigator and California Medical Device Senior Investigator with more than twenty years of experience
  • Sworn Government-POST Certified Criminal Investigator and Lead Trainer 
  • Member of the Regulatory Affairs Professionals Society (RAPS)
  • Member of the Association for the Advancement of Medical Instruments (AAMI)
Kheriaty-2-1

Aaron Kheriaty, M.D.

Medical Ethics Advisor
  • 15 years of experience as a psychiatrist
  • Chairman of the medical ethics committee at the CA Department of State Hospitals
  • Professor of Psychiatry at the University of California, Irvine School of Medicine and Director of the Medical Ethics Program at UCI Health
  • Published in the Wall Street Journal and the Washington Post
  • Authored books and articles for professional and lay audiences on bioethics, social science, psychiatry, religion, and culture
MicrosoftTeams-image (44)

Fabio Macciardi, M.D., Ph.D.

Neurogenetics Scientific Advisor
  • Professor of Molecular Psychiatry at UCI, School of Medicine
  • Leads research focused on analyzing the function and evolution of neurocognitive genes and their associated traits
  • His lab identified more than 600,000 expressed discrete TEs in the human brain as major epigenetic regulators of gene expression in various neuropsychiatric disorders
  • Former VP and Director of Genetic Epidemiology and Bioinformatics at Genset SA (France)
Mehdi-Hatamian3264-1024x869

Mehdi Hatamian, Ph.D.

Chief Scientific Advisor
  • 120 patents issued, 50 published scientific papers 
  • 45+ years of engineering experience in the electrical and biomedical spaces
  • Chief Scientist of Central Engineering at Broadcom with a 20-year tenure
  • Former Program Engineer for the NASA Space Shuttle
  • Member of the National Academy of Engineering
  • Currently developing ZICOH and next-generation cancer detection devices and technologies

MILESTONES

September 2016

TABMELT is Granted Australian Patent

TABMELT is issued an Australian Patent.

June 2018

TABMELT Receives United Kingdom Patent

TABMELT receives its United Kingdom Patent.

July 2018

TABMELT Granted Canadian Patent

TABMELT is awarded a Canadian Patent from the Canadian Intellectual Property Office.

June 2019

TABMELT Trademark Registration

TABMELT receives its trademark registration from the USPTO.

February 2021

TABMELT is Awarded Russia Patent

Vivera expands its exclusive global pharmaceutical licensing for use of the novel TABMELT platform to Russia.

August 2021

TABMELT Logo Trademark Registration

The TABMELT logo trademark is registered.

March 2022

Vivera Executes LOI With NINDS of NIH

Vivera executes a letter of intent to enter a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) to assess therapeutic agents for the potential treatments of stuttering disorders.

December 2022

TABMELT Receives Israeli Patent

Vivera expands its exclusive global pharmaceutical licensing for use of the novel TABMELT platform to Israel.

About Vivera

Vivera is an innovative, science-driven biopharma and medtech company located in Southern California. The Company has global exclusivity to license the patented and patent-pending TABMELT sublingual drug delivery system for pharmaceutical use and holds its own issued patents on ZICOH, a smart, dose-controlled electronic prescription dispensing device, and MDZone, a portable telemedicine station. With multiple divisions, including its technologies, biosciences, medical devices, and advanced diagnostics divisions, Vivera is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.

Copyright © 2024 Vivera Biosciences. All rights reserved.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
**The product(s) are in development and not currently commercially available.

TABMELT products are currently under development, have not been reviewed by the FDA and are not available for commercial sale.